Drug Resistance
Is the Problem.
We Engineered a Path Around It.
Sunom's proprietary nucleoside chemistry is designed to bypass the biological gates that cause today's standard-of-care treatments to fail — in both resistant tumors and emerging viral threats.
The Resistance Problem
Nucleoside analogs are the backbone of cancer chemotherapy and antiviral therapy. Yet they fail at predictable biological checkpoints — and no single molecule has bypassed them all at once.
of Gemcitabine is degraded before it ever reaches the tumor.
And of what does survive, resistant tumors can block its entry, block its activation, and repair the damage it causes. The consequence: treatment failure in pancreatic, NSCLC, and triple-negative breast cancer — and no approved small-molecule antivirals for most emerging viral threats.
One platform designed to bypass multiple resistance mechanisms at once.
Our SNM chemistry re-engineers the nucleoside at the molecular level — producing compounds intended to remain stable in circulation, enter resistant cells, activate intracellularly without tumor-derived kinases, and evade DNA repair. The preclinical data supports the thesis.
0.3 µM
IC-50 across 12+ cancer cell lines
Superior
IC-90 potency vs. Gemcitabine in most tested lines
Broad
Spectrum antiviral activity across alpha & flaviviruses